SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
07 10 2022
Historique:
received: 03 09 2021
accepted: 14 09 2022
entrez: 7 10 2022
pubmed: 8 10 2022
medline: 12 10 2022
Statut: epublish

Résumé

TGF-β signaling is involved in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis, representing one of the four major pathways genetically altered in 100% of PDAC cases. TGF-β exerts complex and pleiotropic effects in cancers, notably via the activation of SMAD pathways, predominantly SMAD2/3/4. Though SMAD2 and 3 are rarely mutated in cancers, SMAD4 is lost in about 50% of PDAC, and the role of SMAD2/3 in a SMAD4-null context remains understudied. We herein provide evidence of a SMAD2/3 oncogenic effect in response to TGF-β1 in SMAD4-null human PDAC cancer cells. We report that inactivation of SMAD2/3 in SMAD4-negative PDAC cells compromises TGF-β-driven collective migration mediated by FAK and Rho/Rac signaling. Moreover, RNA-sequencing analyses highlight a TGF-β gene signature related to aggressiveness mediated by SMAD2/3 in the absence of SMAD4. Using a PDAC patient cohort, we reveal that SMAD4-negative tumors with high levels of phospho-SMAD2 are more aggressive and have a poorer prognosis. Thus, loss of SMAD4 tumor suppressive activity in PDAC leads to an oncogenic gain-of-function of SMAD2/3, and to the onset of associated deleterious effects.

Identifiants

pubmed: 36207615
doi: 10.1038/s42003-022-03994-6
pii: 10.1038/s42003-022-03994-6
pmc: PMC9546935
doi:

Substances chimiques

SMAD2 protein, human 0
SMAD3 protein, human 0
SMAD4 protein, human 0
Smad2 Protein 0
Smad3 Protein 0
Smad4 Protein 0
Transforming Growth Factor beta 0
Transforming Growth Factor beta1 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1068

Informations de copyright

© 2022. The Author(s).

Références

Trends Cell Biol. 2001 Nov;11(11):S44-51
pubmed: 11684442
Int J Mol Sci. 2017 May 19;18(5):
pubmed: 28534865
Cell Rep. 2018 Jun 19;23(12):3447-3456
pubmed: 29924989
J Cell Biol. 2002 Dec 9;159(5):881-91
pubmed: 12473693
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Mol Cell Biol. 2008 Nov;28(22):6889-902
pubmed: 18794361
Biochem Biophys Res Commun. 2003 Oct 3;309(4):961-6
pubmed: 13679067
Cell. 2014 May 22;157(5):1146-59
pubmed: 24855950
Curr Opin Cell Biol. 2012 Oct;24(5):569-81
pubmed: 22819514
Pancreas. 2015 May;44(4):660-4
pubmed: 25760429
Genes Dev. 2005 Dec 1;19(23):2783-810
pubmed: 16322555
J Cell Mol Med. 2020 Nov;24(22):13481-13493
pubmed: 33073486
Ann Surg. 2013 Aug;258(2):331-5
pubmed: 23360922
Cancer Res. 2013 Jan 15;73(2):725-35
pubmed: 23139211
Oncogene. 2005 Aug 29;24(37):5742-50
pubmed: 16123807
Front Oncol. 2015 Jul 20;5:155
pubmed: 26258068
Sci Signal. 2014 Sep 30;7(345):ra91
pubmed: 25270257
J Invest Dermatol. 2002 Feb;118(2):211-5
pubmed: 11841535
Nucleic Acids Res. 2021 Jan 8;49(D1):D916-D923
pubmed: 33270111
Oncogene. 2010 Mar 4;29(9):1351-61
pubmed: 20010874
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Mol Cell Biol. 2005 Sep;25(18):8108-25
pubmed: 16135802
Cell Death Dis. 2019 Nov 25;10(12):886
pubmed: 31767842
EMBO J. 2004 Mar 10;23(5):1155-65
pubmed: 14976548
Cell. 2013 Dec 19;155(7):1639-51
pubmed: 24332913
Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7353-7362
pubmed: 30910979
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Clin Oncol. 2019 Apr 1;37(10):790-798
pubmed: 30785827
Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):
pubmed: 28246180
Oncotarget. 2017 Mar 7;8(10):16704-16711
pubmed: 28053288
Cell Commun Signal. 2010 Sep 07;8:23
pubmed: 20822528
Cell. 2006 Jun 2;125(5):929-41
pubmed: 16751102
Nature. 2015 Nov 26;527(7579):525-530
pubmed: 26560028
Mol Cancer. 2011 May 30;10:67
pubmed: 21624123
Braz J Med Biol Res. 2016 Jul 25;49(8):
pubmed: 27464025
Oncotarget. 2014 Jan 15;5(1):277-90
pubmed: 24378395
Oncotarget. 2016 May 10;7(19):27067-84
pubmed: 27008704
Oncogene. 2003 Mar 6;22(9):1317-23
pubmed: 12618756
J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84
pubmed: 16105881
J Biol Chem. 2009 Apr 10;284(15):9755-63
pubmed: 19224917
Exp Cell Res. 2016 Apr 10;343(1):21-27
pubmed: 26607713
Ann Oncol. 2016 Dec;27(12):2268-2274
pubmed: 27733373
Cells Tissues Organs. 2007;185(1-3):123-30
pubmed: 17587818
Dev Cell. 2018 Jun 18;45(6):681-695.e4
pubmed: 29920274
Oncogene. 2004 Feb 5;23(5):1043-51
pubmed: 14762439
J Clin Med. 2017 Jan 05;6(1):
pubmed: 28067794
Transl Oncol. 2020 Nov;13(11):100845
pubmed: 32781367
Pancreas. 1999 Nov;19(4):370-6
pubmed: 10547197
Oncol Rep. 2017 Dec;38(6):3693-3701
pubmed: 29039574
J Biomech Eng. 2017 Feb 1;139(2):
pubmed: 27814431
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Cancer Cell. 2007 Feb;11(2):147-60
pubmed: 17292826
Front Oncol. 2019 Sep 27;9:996
pubmed: 31612115
J Cell Biol. 2007 Dec 3;179(5):1043-57
pubmed: 18056416
Clin Exp Metastasis. 2005;22(6):461-73
pubmed: 16320109
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6686-91
pubmed: 11390996
Pancreatology. 2007;7(5-6):423-35
pubmed: 17898532
Genes Chromosomes Cancer. 1999 Jan;24(1):62-71
pubmed: 9892110
Sci Rep. 2015 Jan 07;5:7656
pubmed: 25563751
Oncotarget. 2017 Mar 14;8(11):17945-17959
pubmed: 28160547
Mol Biol Cell. 2005 Apr;16(4):1987-2002
pubmed: 15689496
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2487-92
pubmed: 18268325
Dev Biol. 2014 Oct 15;394(2):340-56
pubmed: 25127991
J Vis Exp. 2016 Nov 3;(117):
pubmed: 27842376
PeerJ. 2020 Oct 27;8:e10141
pubmed: 33194391
Oncol Rep. 2001 Jan-Feb;8(1):89-92
pubmed: 11115575
Cell. 2016 Feb 25;164(5):1015-30
pubmed: 26898331
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
Nature. 2009 Sep 3;461(7260):99-103
pubmed: 19693013
Cancer Res. 1998 Oct 15;58(20):4752-7
pubmed: 9788633
Cancer Res. 2000 Apr 1;60(7):2002-6
pubmed: 10766191
Neoplasia. 2004 Sep-Oct;6(5):603-10
pubmed: 15548370

Auteurs

Adrien Bertrand-Chapel (A)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Cassandre Caligaris (C)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Tanguy Fenouil (T)

Hospices Civils de Lyon, Institute of Pathology, Groupement Hospitalier Est, Bron, France.
Ribosome, Translation and Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Clara Savary (C)

Cell Death and Childhood Cancers Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Labex DevWeCan, Institut Convergence Plascan, Lyon, France.

Sophie Aires (S)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Sylvie Martel (S)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Paul Huchedé (P)

Cell Death and Childhood Cancers Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Labex DevWeCan, Institut Convergence Plascan, Lyon, France.

Christelle Chassot (C)

EMT and Cancer Cell Plasticity Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Véronique Chauvet (V)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Victoire Cardot-Ruffino (V)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Anne-Pierre Morel (AP)

EMT and Cancer Cell Plasticity Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Fabien Subtil (F)

Service de Biostatistiques, Hospices Civils de Lyon, Lyon France, Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Évolutive, UMR 5558, Villeurbanne, France.

Kayvan Mohkam (K)

Hospices Civils de Lyon, Croix-Rousse University Hospital, Claude Bernard Lyon 1 University, Department of General Surgery & Liver Transplantation, Lyon, France.

Jean-Yves Mabrut (JY)

Hospices Civils de Lyon, Croix-Rousse University Hospital, Claude Bernard Lyon 1 University, Department of General Surgery & Liver Transplantation, Lyon, France.

Laurie Tonon (L)

Plateforme de bioinformatique Gilles Thomas, Fondation Lyon Synergie Cancer, Centre Léon Bérard, Lyon, France.

Alain Viari (A)

Plateforme de bioinformatique Gilles Thomas, Fondation Lyon Synergie Cancer, Centre Léon Bérard, Lyon, France.

Philippe Cassier (P)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Département d'oncologie Médicale, unité de phase 1, Centre Léon Bérard, Lyon, France.

Valérie Hervieu (V)

Hospices Civils de Lyon, Institute of Pathology, Groupement Hospitalier Est, Bron, France.

Marie Castets (M)

Cell Death and Childhood Cancers Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Labex DevWeCan, Institut Convergence Plascan, Lyon, France. marie.castets@lyon.unicancer.fr.

Alain Mauviel (A)

Team "TGF-ß and Oncogenesis", Institut Curie, PSL Research University, INSERM 1021, CNRS 3347, Equipe Labellisée Ligue 2016, 91400, Orsay, France.

Stéphanie Sentis (S)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Laurent Bartholin (L)

TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France. laurent.bartholin@lyon.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH